EGFR mutated non-small cell lung cancer
Conditions
Interventions
None listed
Sponsors
Kyoto Prefectural University of Medicine
1. Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan 2. Department of Respiratory Medicine and Infectious Diseases, Niigata University Graduate School of Medicine and Dental Hospital, Niigata, Japan 3. Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan 4. Department of Respiratory Medicine, Japanese Red Cross Kyoto Daini Hospital, Kyoto, Japan 5. Department of Respiratory Medi
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients with evaluable disease by RECIST (version 1.1) before osimertinib administration 2) NSCLC patients with EGFR active mutation 3) Patients with formalin-fixed, paraffin-embedded blocks that do not interfere with pathological diagnosis and for whom consent for their use can be obtained from the patient.
Exclusion criteria
Exclusion criteria: Patients judged as inappropriate by the physician in charge
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Association between treatment response with osimertinib treatment and patients background | — |
Countries
Japan
Contacts
Public ContactAkihiro Yoshimura
Kyoto Prefectural University of Medicine Pulmonary Medicine
Outcome results
None listed